Why did Calumet (CLMT) hit a new 52-week high despite reporting an adjusted loss and having a negative P/E ratio?

Calumet hit a new 52-week high of $51.57 amid a 40.8% year-over-year quarterly revenue increase to $1.45 billion, which likely fueled investor optimism about top-line growth and operational scale, even though the company reported an adjusted loss of $1.09 per share and carries a negative price-to-earnings ratio.

What do analyst ratings and price targets suggest about market sentiment toward Calumet ahead of its 52-week high?

Analysts maintain a consensus 'Hold' rating for Calumet with an average price target of $48 — below its new 52-week high of $51.57 — indicating that professional analysts are cautious about near-term upside, despite the stock's strong price performance.

Calumet (NASDAQ:CLMT) Hits New 52-Week High - Still a Buy?

Sep 2, 2026

Calumet Specialty Products Partners reached a new 52-week high of $51.57 despite an adjusted loss of $1.09 per share. Quarterly revenue rose 40.8% year-over-year to $1.45 billion, while analysts maintain a consensus "Hold" rating.